ESMO Preceptorship on Prostate Cancer Singapore 2016
Oncology Meeting Resources
15 Dec - 16 Dec, Singapore, Singapore
The ESMO Preceptorship on Prostate Cancer Singapore 2016 was designed for learning about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer, understanding essentials in the assessment and multidisciplinary treatment of prostate cancer and learning about advances in treatment and novel targets in prostate cancer.
Presentations of the ESMO Preceptorship on Prostate Cancer Singapore 2016 are available to ESMO members according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
|Presenter||Presentation title||Session title|
|A. Alip, IN||Primary Hormone-Refractory Prostate Cancer||Session 4 Initial Systemic Therapy|
|M. Khanderia, IN||Metastatic Prostate Cancer||Session 4 Initial Systemic Therapy|
|R. Kanesvaran, SG||Second-Line Hormonal Therapies||Session 5 Castration Resistant Prostate Cancer (CRPC)|
|J. Tuan, SG||Isotope Therapies And Palliative Radiotherapy||Session 5 Castration Resistant Prostate Cancer (CRPC)|
|K. Lu, TW||Castration-Resistant Prostate Cancer Re-challenging Abiraterone||Session 5 Castration Resistant Prostate Cancer (CRPC)|
|F. A. Ansari, IN||Metastatic Carcinoma Prostate||Session 5 Castration Resistant Prostate Cancer (CRPC)|
|A. Azad, AU||Bone Targeting (Bisphosphonates and RANK Ligands)||Session 6 Immunotherapy and Bone-Targeting|
|A. Azad, AU||Immunotherapy and Other New Drug Targets||Session 6 Immunotherapy and Bone-Targeting|
|J. Jamnasi, ID||Metastatic Prostate Cancer||Session 6 Immunotherapy and Bone-Targeting|
|H. Sanjay, IN||Castrate Resistant Metastatic Carcinoma Prostate||Session 6 Immunotherapy and Bone-Targeting|